A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission

Purpose of investigation: To determine the effect of imatinib on progression-free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR). Methods: 35 patients were enrolled between 10/2002 and 1/2005. Eligible patients received imatinib at 400 mg daily orally. Results: One patient withdrew consent, and two patients received protocol therapy in first remission and were excluded. Five patients were removed for possibly related toxicity. No associations were seen between PDGF-R staining and PFS. Conclusions: Treatment with imatinib for patients with ovarian cancer in second CCR or greater did not prolong the PFS beyond the historical estimate.

Imatinib; Ovarian cancer; Peritoneal; Remission

[1] Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A. et al.: “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2003, 21, 3194.

[2] Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S. et al.: “Intraperitoneal cisplatin and paclitaxel in ovarian cancer”. N. Engl. J. Med., 2006, 354, 34.

[3] Markman M., Markman J.,Webster K., Zanotti K., Kulp B., Peterson G. et al.: “Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design”. J. Clin. Oncol., 2004, 22, 3120.

[4] Westermark B., Heldin C.H.: “Platelet-derived growth factor. Structure, function and implications in normal and malignant cell growth”. Acta Oncol., 1993, 32, 101.

[5] Dabrow M.B., Francesco M.R., McBrearty F.X., Caradonna S.: “The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium”. Gynecol. Oncol., 1998, 71, 29.

[6] Sariban E., Sitaras N.M., Antoniades H.N., Kufe D.W., Pantazis P.: “Expression of platelet-derived growth factor (PDGF)-related transcripts and synthesis of biologically active PDGF-like proteins by human malignant epithelial cell lines”. J. Clin. Invest., 1988, 82, 1157.

[7] Henriksen R., Funa K., Wilander E., Backstrom T., Ridderheim M., Oberg K.: “Expression and prognostic significance of plateletderived growth factor and its receptors in epithelial ovarian neoplasms”. Cancer Res., 1993, 53, 4550.

[8] Versnel M.A., Haarbrink M., Langerak A.W., de Laat P.A., Hagemeijer A., van der Kwast T.H. et al.: “Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo”. Cancer Genet. Cytogenet., 1994, 73, 60.

[9] Schmandt R.E., Broaddus R., Lu K.H., Shvartsman H., Thornton A., Malpica A. et al.: “Expression of c-ABL, c-KIT, and plateletderived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium”. Cancer, 2003, 98, 758.

[10] Rustin G.J., Nelstrop A.E., Bentzen S.M., Piccart M.J., Bertelsen K.: “Use of tumour markers in monitoring the course of ovarian cancer”. Ann. Oncol., 1999, 10, 21.

[11] Apte S.M., Fan D., Killion J.J., Fidler I.J.: “Targeting the plateletderived growth factor receptor in antivascular therapy for human ovarian carcinoma”. Clin. Cancer Res., 2004, 10, 897.

[12] Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M. et al.: “Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome”. N. Engl. J. Med., 2001, 344, 1038.

[13] Coleman R.L., Broaddus R.R., Bodurka D.C., Wolf J.K., Burke T.W., Kavanagh J.J. et al.: “Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers”. Gynecol. Oncol., 2006, 101, 126.

[14] Alberts D.S., Liu P.Y., Wilczynski S.P., Jang A., Moon J., Ward J.H. et al.: “Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)”. Int. J. Gynecol. Cancer, 2007.

[15] Panageas K.S., Ben-Porat L., Dickler M.N., Chapman P.B., Schrag D.: “When you look matters: the effect of assessment schedule on progression-free survival”. J. Natl. Cancer Inst., 2007, 99, 428.

[16] Bristow R.E., Lagasse L.D., Karlan B.Y.: “Secondary surgical cytoreduction for advanced epithelial ovarian cancer”. Cancer, 1996, 78, 2049.

[17] Leitao M.M. Jr., Kardos S., Barakat R.R., Chi D.S.: “Tertiary cytoreduction in patients with recurrent ovarian carcinoma”. Gynecol. Oncol., 2004, 95, 181.

[18] McCreath W.A., Chi D.S.: “Surgical cytoreduction in ovarian cancer”. Oncology (Williston Park), 2004, 18, 645.